| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MSH6; GTBP; DNA mismatch repair protein Msh6; hMSH6; G/T mismatch-binding protein; GTBP; GTMBP; MutS-alpha 160 kDa subunit; p160 |
| Entrez GeneID | 2956 |
| WB Predicted band size | Calculated MW: 153 kDa; Observed MW: 163 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthetic peptide of human MSH6 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于MSH6抗体的3篇代表性文献的简要信息，涵盖其应用、局限性和临床意义：
---
1. **文献名称**：*"MSH6 deficiency in human colorectal cancer: A comparison of immunohistochemical and genetic testing"*
**作者**：Suraweera N, et al.
**摘要**：该研究比较了免疫组化(IHC)中MSH6抗体检测与基因测序结果的差异，发现部分MSH6基因突变病例可能因蛋白截短或抗原表位改变导致IHC假阴性，强调联合基因检测以提高林奇综合征诊断准确性。
2. **文献名称**：*"Comparison of monoclonal antibodies against MSH6 protein in detecting mismatch repair deficiency"*
**作者**：Bai H, et al.
**摘要**：研究评估了不同克隆号(如EPR3945、44M2)的MSH6抗体在IHC中的敏感性和特异性，指出克隆44M2对部分错义突变的检测更稳定，为临床选择抗体提供依据。
3. **文献名称**：*"Loss of MSH6 expression in endometrial carcinomas: Correlation with microsatellite instability and prognosis"*
**作者**：Klarskov L, Redman-Müller L.
**摘要**：通过MSH6抗体分析子宫内膜癌中错配修复状态，发现MSH6蛋白缺失与高微卫星不稳定性(MSI-H)及预后不良相关，支持其作为生物标志物用于分层治疗。
---
**扩展方向**：
- **方法优化**：如《Modern Pathology》中Drummond等研究提出多重抗体组合(MSH2/MSH6共表达分析)可减少误判。
- **机制研究**：Watson等(2019)探讨MSH6突变导致抗原表位丢失的分子机制，解释IHC局限性。
如需具体文献年份或期刊，可进一步补充!
The MSH6 antibody is a crucial tool in studying DNA mismatch repair (MMR) mechanisms and associated diseases. MSH6. a protein encoded by the *MSH6* gene, forms a heterodimer with MSH2 to recognize DNA mismatches during replication. This complex is part of the MMR system, which corrects errors to maintain genomic stability. Defects in MSH6 are linked to Lynch syndrome (hereditary nonpolyposis colorectal cancer), where germline mutations in MMR genes (e.g., *MLH1*, *MSH2*, *MSH6*, *PMS2*) predispose individuals to colorectal, endometrial, and other cancers. MSH6 mutations account for ~10% of Lynch cases and often result in microsatellite instability (MSI), a hallmark of MMR deficiency.
In diagnostics, MSH6 antibodies are used in immunohistochemistry (IHC) to detect loss of MSH6 protein expression in tumor tissues, aiding Lynch syndrome screening and cancer subtyping. Loss of MSH6 staining, often paired with retained MSH2. suggests an underlying *MSH6* mutation. Researchers also employ these antibodies in Western blotting and immunofluorescence to study MMR function, cellular responses to DNA damage, and therapeutic targets. Commercially available clones (e.g., EP49. 44/MSH6) vary in specificity, requiring validation for clinical use. MSH6 antibodies thus serve as vital biomarkers for both research and precision oncology, guiding genetic counseling and treatment decisions.
×
